Southern Spine, LLC
$4.8K 2 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Vioptix Inc
Vioptix Inc reported $4,749.49 across General Payments, Research, and Ownership to 73 physicians and teaching hospitals across 73 transactions.
- $4.7K Below-median payer
- All-tracks total
- 73 Below-median volume
- Transactions
- 73 Below-median reach
- Recipients
- +$1.2K
- General Payments vs PY2023
Vioptix Inc reported $4,749.49 across all CMS Open Payments tracks (General + Research + Ownership) to 73 physicians and teaching hospitals in Program Year 2024 - ranking #1720 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $4,749.49, averaging $65.06 per recipient.
Vioptix Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
14/100
Total payments
F
10/100
Transaction volume
F
10/100
Physician reach
F
11/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer vioptix-inc Vioptix Inc
$4.7K · #1720/1,925 · 0.0% industry · PY2024
- TOT $4.7K
- RANK #1720
- SHARE 0.0%
- TXN 73
- RCP 73
- CAT 2
- GEN $4.7K
- ΔGEN +$1.2K
- TOP1 28.5%
- PY 2024
Volume peers
Nearest volume peer: Southern Spine, LLC ($4.8K)
Vioptix Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Vioptix Inc's CMS-reported General Payments increased by $1.2K (+35.2%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: VIOPTIX INCPY2023: VIOPTIX INCPY2024: Vioptix Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $3,512.18
- PY2024
- $4,749.49
What the Data Shows for Vioptix Inc
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Vioptix Inc that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
Of the 2 general-payment categories charted below, "Food and Beverage" is the largest at $4.5K across 72 transactions, 94.7% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Vioptix Inc made 2 types of general payments. "Food and Beverage" is the largest category at $4.5K, 94.7% of General Payments.
How Vioptix Inc divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $4.5K | 72 | 94.7% |
| Consulting Fee | $250.00 | 1 | 5.3% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $2,114.22 (44.5%) of $4,749.49 in this company's General Payments records across 64 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Vioptix Inc
The five named recipients with the highest reported General Payments from this company
- 1
Elisabeth Potter
$1,353.49 across 2 reported transactions
- 2
Alexandra Kejner
$250.00 across 1 reported transactions
- 3
Kristen Rezak
$183.12 across 2 reported transactions
- 4
Eliza-Jasmine Tran
$174.47 across 2 reported transactions
- 5
Justin Van Hoorebeke
$153.14 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Vioptix Inc ranks #1720 of 1,925 by total payments (bottom 11% by spend) but is notably more concentrated than that alone would suggest -- #1,042 of 1,838 by HHI (bottom 43% least concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Geron Corporation : $91.2K total payments, HHI 985
- Macrogenics, Inc. : $1.1K total payments, HHI 985
- Rti Surgical, Inc : $1.4M total payments, HHI 982
- OssDsign Incorporated : $88.5K total payments, HHI 981
- Mf Med : $630.54 total payments, HHI 979
- B. Braun Medical Inc. : $221.2K total payments, HHI 975
- Vioptix Inc (this company) : $4.7K total payments, HHI 971
- Bolton Medical Inc : $2.2M total payments, HHI 970
- Ge Healthcare : $6.4M total payments, HHI 966
- Occlutech US LLC : $1.2M total payments, HHI 961
- Cytyc Surgical Products, LLC : $12.4K total payments, HHI 961
- BioXcel Therapeutics, Inc. : $116.0K total payments, HHI 958
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Vioptix Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Vioptix Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Vioptix Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Ortho Technology, Inc
$4.7K 14 recipients
Compare payment profiles
Winter Innovations, Inc.
$4.7K 7 recipients
Compare payment profiles
Sensus Healthcare, Inc.
$4.7K 128 recipients
Compare payment profiles
Linus Health, Inc.
$4.8K 338 recipients
Compare payment profiles
Asuragen, Inc.
$4.9K 6 recipients
Compare payment profiles
Put this to use
Vioptix Inc ranks #1720 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Vioptix Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.